This educational program is intended for physicians, nurses, pharmacists, and other healthcare professionals who treat patients with advanced systemic mastocytosis.
Upon completion of this activity, participants should be able to:
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Prithviraj Bose, MD
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Prithviraj Bose, MD, has disclosed that he has receiving consulting fees from AbbVie, Blueprint Medicines, Bristol-Myers Squibb, CTI BioPharma, Incyte, Karyopharm, Novartis, Pharma Essentia, and Sierra Oncology and funds for research support from Astellas, Blueprint Medicines, Bristol-Myers Squibb, Cogent, Constellation, CTI BioPharma, Incyte, Ionis, Kartos, NS Pharma, Pfizer, and Promedior.
Ilene A. Galinsky, NP
Senior Research Program Adult Leukemia Nurse Practitioner
Department of Leukemia
Dana-Farber Cancer Institute/Brigham and Womens Hospital
Ilene A. Galinsky, NP, has disclosed that she has received consulting fees from AbbVie, Jazz, Novartis, and Pfizer.
Caitlin R. Rausch, PharmD, BCOP
Clinical Pharmacy Specialist, Leukemia
Division of Pharmacy
University of Texas MD Anderson Cancer Center
Caitlin R. Rausch, PharmD, has no relevant conflicts of interest to report.
Rachael M. Andrie, PhD
Rachael Andrie, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD
Senior Clinical Editor
Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Associate Managing Editor
Krista Marcello has no relevant conflicts of interest to report.
Kevin Obholz, PhD
Editorial Director, Hematology/Oncology
Timothy A. Quill, PhD
Senior Managing Editor
Timothy Quill, PhD, has no relevant conflicts of interest to report.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-106-H01-P.
Type of Activity: Application
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 12, 2022, through April 11, 2023:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
This program has been made available online.
The goal of this program is to improve the knowledge and competence of learners to incorporate newer patient-centered therapies into the management of patients with advanced systemic mastocytosis.